Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3076 to 3090 of 8970 results

  1. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  2. Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.

  3. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  4. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

  5. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

  6. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  7. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  8. Digitally enabled therapies for adults with depression: early value assessment (HTG675)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.

  9. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

  10. Plus Sutures for preventing surgical site infection (HTG586)

    Evidence-based recommendations on Plus Sutures for preventing surgical site infection.

  11. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

  12. Danis stent for acute oesophageal variceal bleeding (HTG574)

    Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.

  13. Leukomed Sorbact for preventing surgical site infection (HTG567)

    Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery.

  14. The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (HTG566)

    Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.

  15. The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)

    Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.